vortioxetine (Q3563148)

508233-74-7 (English)

18 November 2016

chemical formula

C₁₈H₂₂N₂S

1 reference

508233-74-7 (English)

18 November 2016

canonical SMILES

CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CCNCC3)C

1 reference

508233-74-7 (English)

https://www.whocc.no/atc_ddd_index/?code=N06AX26

18 November 2016

defined daily dose

10 milligram

route of administration

oral administration

1 reference

reference URL

1 reference

14 February 2018

1 reference

14 February 2018

World Health Organisation international non-proprietary name

vortioxetine (English)

1 reference

vortioxetine (English)

medical condition treated

3 October 2016

anxiety

1 reference

Drug Indications Extracted from FAERS

significant drug interaction

2 October 2018

clopidogrel

1 reference

A reference set of clinically relevant adverse drug-drug interactions

eptifibatide

1 reference

A reference set of clinically relevant adverse drug-drug interactions

iloprost

1 reference

A reference set of clinically relevant adverse drug-drug interactions

prostacyclin

1 reference

A reference set of clinically relevant adverse drug-drug interactions

tirofiban

1 reference

A reference set of clinically relevant adverse drug-drug interactions

abciximab

1 reference

A reference set of clinically relevant adverse drug-drug interactions

prasugrel

1 reference

A reference set of clinically relevant adverse drug-drug interactions

ticagrelor

1 reference

A reference set of clinically relevant adverse drug-drug interactions

cangrelor

1 reference

A reference set of clinically relevant adverse drug-drug interactions

aspirin

1 reference

A reference set of clinically relevant adverse drug-drug interactions

nabumetone

1 reference

A reference set of clinically relevant adverse drug-drug interactions

naproxen

1 reference

A reference set of clinically relevant adverse drug-drug interactions

celecoxib

1 reference

A reference set of clinically relevant adverse drug-drug interactions

Diclofenac

1 reference

A reference set of clinically relevant adverse drug-drug interactions

piroxicam

1 reference

A reference set of clinically relevant adverse drug-drug interactions

meloxicam

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(RS)-fenoprofen

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(+-)-flurbiprofen

1 reference

A reference set of clinically relevant adverse drug-drug interactions

ibuprofen

1 reference

A reference set of clinically relevant adverse drug-drug interactions

indomethacin

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(RS)-ketoprofen

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(RS)-etodolac

1 reference

A reference set of clinically relevant adverse drug-drug interactions

sulindac

1 reference

A reference set of clinically relevant adverse drug-drug interactions

parecoxib

1 reference

A reference set of clinically relevant adverse drug-drug interactions

aceclofenac

1 reference

A reference set of clinically relevant adverse drug-drug interactions

tenoxicam

1 reference

A reference set of clinically relevant adverse drug-drug interactions

rac-warfarin

1 reference

A reference set of clinically relevant adverse drug-drug interactions

acenocoumarol

1 reference

A reference set of clinically relevant adverse drug-drug interactions

phenindione

1 reference

A reference set of clinically relevant adverse drug-drug interactions

rivaroxaban

1 reference

A reference set of clinically relevant adverse drug-drug interactions

apixaban

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

physically interacts with

5-hydroxytryptamine receptor 1A

1 reference

5-hydroxytryptamine receptor 1B

17 August 2016

1 reference

5-hydroxytryptamine receptor 2A

17 August 2016

1 reference

5-hydroxytryptamine receptor 2C

17 August 2016

1 reference

5-hydroxytryptamine receptor 3A

17 August 2016

1 reference

5-hydroxytryptamine receptor 5A

17 August 2016

1 reference

5-hydroxytryptamine receptor 6

17 August 2016

1 reference

5-hydroxytryptamine receptor 7

17 August 2016

1 reference

solute carrier family 6 member 4

17 August 2016

1 reference

https://nctr-crs.fda.gov/fdalabel/ui/spl-summaries/criteria/343802

17 August 2016

legal status (medicine)

boxed warning

1 reference

reference URL

imported from Wikimedia project

FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links. (English)

pregnancy category

US pregnancy category C

1 reference

English Wikipedia

selective serotonin reuptake inhibitor

2 references

5 March 2018

15 March 2018

1 reference

15 March 2018

1 reference

MeSH descriptor ID

C557874

serotonin 5-HT1 receptor agonist

15 March 2018

1 reference

MeSH descriptor ID

C557874

Serotonin 5-HT1 Receptor Antagonists

15 March 2018

1 reference

InChI=1S/C18H22N2S/c1-14-7-8-17(15(2)13-14)21-18-6-4-3-5-16(18)20-11-9-19-10-12-20/h3-8,13,19H,9-12H2,1-2H3

15 March 2018

Vortioxetine

0 references

Identifiers

InChI

1 reference

508233-74-7 (English)

18 November 2016

1 reference

508233-74-7 (English)

18 November 2016

2 references

vortioxetine (English)

18 November 2016

https://commonchemistry.cas.org/detail?cas_rn=508233-74-7

8 April 2021

1 reference

Vortioxetine (English)

18 November 2016

2 references

508233-74-7 (English)

18 November 2016

Reaxys registry number

11341374

1 reference

vortioxetine (English)

3 October 2016

ChEBI ID

76016

mapping relation type

2 references

VORTIOXETINE (English)

18 November 2016

International Chemical Identifier

InChI

InChI=1S/C18H22N2S/c1-14-7-8-17(15(2)13-14)21-18-6-4-3-5-16(18)20-11-9-19-10-12-20/h3-8,13,19H,9-12H2,1-2H3

1 reference

VORTIOXETINE (English)

18 November 2016

2 references

inferred from InChIKey

Hazardous Substances Data Bank

1 reference

1 reference

28 October 2019

VORTIOXETINE (English)

10 May 2021

DSSTox substance ID

DTXSID80965062

1 reference

DSSTOX compound identifier

0 references

1 reference

ECHA Substance Infocard database

ECHA Substance Infocard ID

100.258.748

27 December 2018

ECHA Substance Infocard ID

1-[2-(2,4-dimethylphenyl)sulfanylphenyl]piperazine (English)

quotation

CAS no.: 508233-74-7 (English)

100.258.748

1 reference

ECHA Substance Infocard database

ECHA Substance Infocard ID

100.258.748

27 December 2018

1-[2-(2,4-dimethylphenyl)sulfanylphenyl]piperazine (English)

quotation

CAS no.: 508233-74-7 (English)

ATC code

N06AX26

0 references

1 reference

vortioxetine (English)

18 November 2016

Vortioxetine

0 references

0 references

1 reference

vortioxetine (English)

18 November 2016

DrugBank ID

DB09068

1 reference

Human Metabolome Database ID

HMDB0259875

2 references

based on heuristic

inferred from InChIKey

2 references

vortioxetine (English)

18 November 2016

MedlinePlus drug identifier

0 references

1 reference

vortioxetine (English)

18 November 2016

0 references

1 reference

1 reference

https://docs.openalex.org/download-snapshot/snapshot-data-format

vortioxetine (English)

3 October 2016

0 references

1 reference

28 October 2013

Microsoft Academic ID

0 references

1 reference

26 January 2022

UK Parliament thesaurus ID

548667

subject named as

Vortioxetine

0 references

UMLS CUI

C3661282

1 reference

vortioxetine (English)